Ooi G T, Tseng L Y, Rechler M M
Growth and Development Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Biochem Biophys Res Commun. 1992 Dec 15;189(2):1031-7. doi: 10.1016/0006-291x(92)92307-j.
IGFBP-1 and IGFBP-2 mRNAs are increased in the livers of streptozotocin-diabetic rats. A corresponding increase is observed in transcription of the IGFBP-1 but not the IGFBP-2 gene, indicating that the increase in steady-state levels of IGFBP-2 mRNA is a post-transcriptional effect. IGFBP-1 and IGFBP-2 mRNAs also differ in the rapidity of their response to insulin treatment: hepatic IGFBP-1 mRNA is normalized within 1 h, IGFBP-2 mRNA decreases more slowly. These differences suggest that IGFBP-2 may provide more chronic adaptation to metabolic change than IGFBP-1.
在链脲佐菌素诱导的糖尿病大鼠肝脏中,胰岛素样生长因子结合蛋白1(IGFBP-1)和胰岛素样生长因子结合蛋白2(IGFBP-2)的信使核糖核酸(mRNAs)水平升高。IGFBP-1基因的转录有相应增加,但IGFBP-2基因没有,这表明IGFBP-2 mRNA稳态水平的升高是转录后效应。IGFBP-1和IGFBP-2 mRNAs对胰岛素治疗的反应速度也有所不同:肝脏中的IGFBP-1 mRNA在1小时内恢复正常,而IGFBP-2 mRNA下降得更慢。这些差异表明,与IGFBP-1相比,IGFBP-2可能为代谢变化提供更持久的适应性。